drugset / Trial / NCT03608878
Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype
RandomizedParallel-groupOpen-labelTreatment
Summary
TACE against HCC is the standard of care for BCLC stage B patients. In this exploratory study, the investigators assess the efficacy of TACE with or without adagloxad simolenin/OBI-821 treatment in GALNT14 "non-TT" HCC population.
Timeline
- Start
- 2019-04-26
- Primary completion
- 2019-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OBI-821 | Other / unclassified | — | — |
| Subject | adagloxad simolenin | Vaccine | — | — |